194 related articles for article (PubMed ID: 36054935)
1. Effect of tacrolimus on soluble costimulatory molecules in patients with refractory myasthenia gravis.
Wu H; Chen L; Zhou X; Wu Y; Yan Y; Zhu Y; Zhao C; Xue Q
J Neuroimmunol; 2022 Nov; 372():577955. PubMed ID: 36054935
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic and Immunoregulatory Effects of Tacrolimus in Patients with Refractory Generalized Myasthenia Gravis.
Wu H; Wang Z; Xi J; Liu J; Yan C; Song J; Wang L; Jing S; Wang Y; Zhao C
Eur Neurol; 2020; 83(5):500-507. PubMed ID: 32932253
[TBL] [Abstract][Full Text] [Related]
3. Unbalanced expression of membrane-bound and soluble inducible costimulator and programmed cell death 1 in patients with myasthenia gravis.
Yan X; Gu Y; Wang C; Sun S; Wang X; Tian J; Wang M; Ji X; Duan X; Gao H; Fang Q; Dong W; Zhang X; Xue Q
Clin Immunol; 2019 Oct; 207():68-78. PubMed ID: 31374257
[TBL] [Abstract][Full Text] [Related]
4. Clinical efficacy of tacrolimus for treating myasthenia gravis and its influence on lymphocyte subsets.
Bao J; Gao S; Weng Y; Zhu J; Ye H; Zhang X
Rev Neurol (Paris); 2019; 175(1-2):65-72. PubMed ID: 30293884
[TBL] [Abstract][Full Text] [Related]
5. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
[TBL] [Abstract][Full Text] [Related]
6. Long-term efficacy and safety of tacrolimus in young children with myasthenia gravis.
Zhang Y; Zhang M; Zhang L; Zhou S; Li W
J Clin Neurosci; 2023 Oct; 116():93-98. PubMed ID: 37669613
[TBL] [Abstract][Full Text] [Related]
7. Low-dose rituximab every 6 months for the treatment of acetylcholine receptor-positive refractory generalized myasthenia gravis.
Lu J; Zhong H; Jing S; Wang L; Xi J; Lu J; Zhou L; Zhao C
Muscle Nerve; 2020 Mar; 61(3):311-315. PubMed ID: 31875994
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy and immunological impact of tacrolimus in Chinese patients with generalized myasthenia gravis.
Zhao CB; Zhang X; Zhang H; Hu XQ; Lu JH; Lu CZ; Xiao BG
Int Immunopharmacol; 2011 Apr; 11(4):519-24. PubMed ID: 21195813
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of tacrolimus in Osserman grade III and Osserman grade IV Myasthenia Gravis.
Zhao LN; Liang Y; Fang XJ; Liu XM; Jiang QL; Wang SS; She SF; Cao M
Clin Neurol Neurosurg; 2018 Oct; 173():70-76. PubMed ID: 30092406
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of steroid-dependent myasthenia gravis patients with low-dose tacrolimus.
Nagaishi A; Yukitake M; Kuroda Y
Intern Med; 2008; 47(8):731-6. PubMed ID: 18421189
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of tacrolimus therapy for myasthenia gravis: A single arm meta-analysis.
Wang L; Xi J; Zhang S; Wu H; Zhou L; Lu J; Zhang T; Zhao C
J Clin Neurosci; 2019 May; 63():160-167. PubMed ID: 30827886
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Safety and Efficacy of Tacrolimus in Myasthenia Gravis.
Kim YH; Shin HY; Kim SM
Yonsei Med J; 2019 Jul; 60(7):633-639. PubMed ID: 31250577
[TBL] [Abstract][Full Text] [Related]
13. [Therapeutic efficacy and safety of tacrolimus for intractable myasthenia gravis: a report of 36 patients].
Feng HY; Liu WB; Qiu L; Huang X; Huang RX
Zhonghua Yi Xue Za Zhi; 2011 Dec; 91(45):3190-2. PubMed ID: 22333101
[TBL] [Abstract][Full Text] [Related]
14. Promising efficacy of Low-Dose rituximab in Muscle specific kinase antibody positive Myasthenia Gravis.
Yang X; Zhang W; Chang X; Li Z; Du R; Guo J
Neurosci Lett; 2024 Jan; 818():137561. PubMed ID: 37984485
[TBL] [Abstract][Full Text] [Related]
15. Zytux in Refractory Myasthenia Gravis: A Multicenter, Open-Labeled, Clinical Trial Study of Effectiveness and Safety of a Rituximab Biosimilar.
Fatehi F; Moradi K; Okhovat AA; Shojatalab G; Sedighi B; Boostani R; Sarraf P; Haghi Ashtiani B; Ghasemi M; Moussavi S; Anjidani N; Nafissi S
Front Neurol; 2021; 12():682622. PubMed ID: 34512504
[No Abstract] [Full Text] [Related]
16. A Randomized Open-Labeled Trial of Methotrexate as a Steroid-Sparing Agent for Patients With Generalized Myasthenia Gravis.
Di L; Shen F; Wen X; Lu Y; Zhu W; Wang M; Da Y
Front Immunol; 2022; 13():839075. PubMed ID: 35371086
[TBL] [Abstract][Full Text] [Related]
17. No correlation between acetylcholine receptor antibody concentration and individual clinical symptoms of myasthenia gravis: A systematic retrospective study involving 67 patients.
Wang L; Wang S; Yang H; Han J; Zhao X; Han S; Zhang Y; Lv J; Zhang J; Li M; Ji Y; Zhou S; He X; Fang H; Yang J; Zhang Y; Zhang Q; Gao P; Gao F
Brain Behav; 2021 Jul; 11(7):e02203. PubMed ID: 34075720
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study.
Howard JF; Utsugisawa K; Benatar M; Murai H; Barohn RJ; Illa I; Jacob S; Vissing J; Burns TM; Kissel JT; Muppidi S; Nowak RJ; O'Brien F; Wang JJ; Mantegazza R;
Lancet Neurol; 2017 Dec; 16(12):976-986. PubMed ID: 29066163
[TBL] [Abstract][Full Text] [Related]
19. [The Myasthenia Gravis Activities of Daily Living score and associated factors to distinguish the refractory phase in generalized myasthenia gravis patients with 5 years or more disease duration].
Sugimoto T; Yamawaki T; Naito H; Ohno N; Giga M; Kono T; Ochi K; Kohriyama T; Nomura E; Maruyama H
Rinsho Shinkeigaku; 2022 Dec; 62(12):915-921. PubMed ID: 36450489
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of tacrolimus for myasthenia gravis: a systematic review and meta-analysis.
Wang L; Zhang S; Xi J; Li W; Zhou L; Lu J; Lu J; Zhang T; Zhao C
J Neurol; 2017 Nov; 264(11):2191-2200. PubMed ID: 28921038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
